Mangoceuticals, Inc. Announces Proposed Series D Preferred Stock Terms and Combined 2025 and 2026 Annual Meeting Date

On November 2, 2026, the holder of all 50 issued and outstanding shares of Mangoceuticals’ Series B Convertible Preferred Stock approved the terms of a new Series D Preferred Stock. The holder also approved an amendment to the certificate of designations governing the Series B shares.